CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
bioMérieux (BIM) is a French biotech company, established in 1963 and based in Marcy-l'Étoile, France. The company is a global leader in clinical microbiology and providing solutions for managing infectious diseases. Moreover, bioMérieux caters to the cosmetics, agri-food and pharmaceutical industries. The company operates 18 production and 20 R&D sites, in addition to 42 subsidiaries globally. With 9,800 employees, bioMérieux is present in more than 150 countries. bioMérieux is listed on the Euronext Paris. Explore the bioMérieux share price (BIM) at Capital.com.
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024
Read our reviews to find out more about us
Read the feedback from our clients, whatever their experience level.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.